SLS Stock Flat After-Hours Despite Narrower Per-Share Q2 Loss — Investors Eye End Of GPS Quiet Period
The biotech, focused on novel cancer therapies, reported a net loss of $9.6 million, or $0.05 per share, for the quarter ended June 30. Final analysis in the REGAL trial will follow the company recording the 80th patient death. In a LinkedIn post in early July, when the trial stood at 78 of the required … Read more